GUFICBIO Gufic Biosciences Q1 FY27 results (Apr–Jun 2026) and concall
Gufic Biosciences delivered strong Q1 FY27 results with robust revenue and profit growth, driven by improved margins and increasing capacity utilization at its Indore facility. The company is strategically expanding its international footprint with an IP-led model and advancing its product pipeline, including GLP-1 CMO operations and new aesthetic fillers, while anticipating operating leverage gains from Indore by mid-FY28.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 15.0%, net profit up 83.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 204 | 208 | 205 | 227 | 230 +13% | 231 +11% | 252 +23% | 261 +15% |
| EBITDA | 39 | 34 | 27 | 32 | 36 −8% | 36 +6% | 46 +70% | 47 +47% |
| Net profit | 22 | 19 | 8 | 12 | 15 −32% | 16 −16% | 21 +163% | 22 +83% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
